



## **INGENUITY SYSTEMS ANNOUNCES MULTI-YEAR DEAL WITH BRISTOL-MYERS SQUIBB FOR IPA**

**Redwood City, CA – September 2, 2008** – Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced a multi-year agreement with Bristol-Myers Squibb Company (NYSE: BMY) for use of the Ingenuity Pathways Analysis (IPA) software application. Bristol-Myers Squibb will continue to leverage IPA for the interpretation, modeling, and visualization of genomics and proteomics data to identify key biological insights to accelerate their drug discovery programs.

The agreement provides enterprise-wide access to IPA for Bristol-Myers Squibb research scientists. Research teams have access to the newest version of IPA, which supports Affymetrix GeneChip® Exon Arrays, supports many new species, and includes recent enhancements such as the Path Designer publishing tool and capabilities for metabolomics, biomarker, and toxicology research. The all-in-one nature of IPA ensures easy workflows for maximum efficiency across Bristol-Meyers Squibb's global organization.

"We are very pleased that Bristol-Myers Squibb has chosen Ingenuity as a partner for its drug discovery and development programs," commented Sean Scott, SVP Commercial Operations, Ingenuity Systems. "Bristol-Myers Squibb has been a highly valued customer since 2004 and we regard their license renewal and multi-year commitment as confirmation that IPA is an integral part of their discovery programs."

### **About Ingenuity Pathways Analysis**

Ingenuity Pathways Analysis is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of [peer-reviewed journals](#).

### **About Ingenuity Systems®**

Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. Our long-term focus on innovation in semantic search has allowed us to create groundbreaking technologies that have one common goal —to generate maximum value from all types of biological and chemical knowledge. Ingenuity offerings leverage the Ingenuity Knowledge Base, which contains uniquely structured literature findings that allow scientists to ask complex biological questions and gain rapid insight into their experimental data or systems of interest. Today, Ingenuity's solutions are used by thousands of

researchers at hundreds of leading pharmaceutical, biotechnology, academic, and government research institutions worldwide. [www.ingenuity.com](http://www.ingenuity.com)

**Contact:**

Heidi Bullock  
Director, Marketing  
Ingenuity Systems  
650.381.5150  
# # #